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Dopamine is a key regulator of glucose metabolism in the central nervous system. However,
dopamine is also present in the periphery andmay have direct effects on insulin-sensitive tissues.
Dopamine receptor 2 (D2R) agonist bromocriptine is a FDA-approved drug for type 2 diabetes.
Herein, we explored the role of peripheral dopamine and its receptors in regulating glucose uptake
and metabolism on insulin-sensitive tissues. Peripheral dopamine effect in [3H]2-deoxyglucose
uptake in insulin-sensitive tissues was tested in vivo in rats. Direct effects on [3H]2-deoxyglucose
uptake, insulin receptor phosphorylation, and regulation of metabolic function were tested ex vivo
in the liver, soleus muscle, and white and brown adipose tissues. Bromocriptine and the
antagonists domperidone, D2R antagonist, and haloperidol, antagonist of both dopamine
receptor 1 (D1R) and D2R, were used to disclose dopamine receptors’ involvement.
Peripheral dopamine increases glucose uptake in vivo. Ex vivo, only dopamine increased
glucose uptake in the soleus, while bromocriptine increased it in the liver; the effects were
reverted by haloperidol and domperidone, respectively. In adipose tissue, domperidone
reverted dopamine- and bromocriptine-mediated potentiation of insulin-induced glucose
uptake, but in turn increased the insulin receptor, Akt, AMPK, HSL, ACC, and ACL,
phosphorylation. In the soleus muscle, AMPK-phosphorylation increased with
bromocriptine and dopamine whose effects were suppressed by domperidone and
haloperidol.
In conclusion, peripheral dopamine stimulates glucose uptake with its receptors being
differentially involved in glucose uptake in insulin-sensitive tissues. Dopamine also has a
role in lipid metabolism in white adipose tissue. Altogether, these results suggest that
peripheral modulation of the dopaminergic system should be further evaluated as a
putative therapeutic approach for metabolic disorders.
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INTRODUCTION
Dopamine is the predominant catecholamine neurotransmitter in
the mammalian central nervous system (CNS) regulating
neuronal functions such as locomotor activity and movement
coordination, cognition, emotion, positive reinforcement, food
intake, and endocrine homeostasis (Missale et al., 1998).
Dopamine exerts its actions through binding to G
protein–coupled receptors, classified in two subfamilies: the
dopamine D1-like receptors family (D1R and D5R), which are
linked to a stimulatory effect on adenylyl cyclase and therefore
increase cyclic adenosine monophosphate (cAMP) levels, and the
dopamine D2-like receptors (D2R, D3R, and D4R) that have an
inhibitory effect on adenylyl cyclase, leading to a decrease in
cAMP levels (Bone et al., 2017; Bucolo et al., 2019).
Outside the CNS, dopamine derived from the synaptic
terminals of the peripheral nervous system regulates several
processes such as hormone secretion, vascular tone, renal
function, and gastrointestinal motility (Asghar et al., 2011;
Bucolo et al., 2019), also playing a key role in the central
regulation of glucose metabolism and energy balance. Mice
lacking whole body D2R are glucose intolerant and exhibit
abnormal insulin secretion (Garcia-Tornadú et al., 2010).
Moreover, adverse metabolic profiles in mice, such as
hyperinsulinemia, weight gain, and glucose intolerance, were
observed after dopamine receptors blockade with haloperidol,
a dopamine D1R + D2R antagonist, and after administration of
some antipsychotic drugs in humans (de Leeuw van Weenen
et al., 2010; Garcia-Tornadú et al., 2010; Freyberg and McCarthy,
2017). In agreement with this role, the D2R agonist
bromocriptine was shown to improve glycemic control and
glucose tolerance in obese type 2 diabetic patients, being
approved by the FDA for the treatment of type 2 diabetes.
Such effects were described to be associated with increased
hypothalamic dopamine levels and inhibition of excessive
sympathetic tone within the central nervous system (Via et al.,
2010; DeFronzo, 2011; Lopez Vicchi et al., 2016). More recently,
we showed that bromocriptine remodels adipose tissue
dopaminergic signaling and upregulates catabolic pathways,
improving the metabolic profile in type 2 diabetes (Tavares
et al., 2021). Such effects may be involved in bromocriptine
therapeutic action, given the impaired expression of dopamine
receptors in the visceral adipose tissue of insulin-resistant
patients, as well as the correlation of dopamine D1R
expression with insulin receptors and metabolic mediators
(Tavares et al., 2021). Altogether, the findings of Tavares et al.
(2021) suggest a possible peripheral action of bromocriptine on
glucose metabolism. In fact, several evidences also point toward
the role of dopamine in the regulation of peripheral glucose
homeostasis and insulin sensitivity and secretion: 1) the
dopamine transporter—the vesicular monoamine transporter
type 2—was found to be expressed by insulin-producing β
cells, but not in glucagon or somatostatin-expressing ones
(Ustione et al., 2013; Maffei et al., 2015; Chaudhry et al., 2016;
Bucolo et al., 2019); 2) dopamine D2-like receptors are expressed
in pancreatic β-cells, and its targeting through exogenous
dopamine inhibits glucose-stimulated insulin secretion from
the isolated islets (Ustione et al., 2013; Chaudhry et al., 2016,
2016); 3) dopamine is produced by rat adipocytes isolated from
mesenteric adipose tissue (Vargovic et al., 2011); and 4) all
dopamine receptors, except the D3R, were found to be
expressed in human white adipose tissue, involved in the
modulation of hormones such as leptin, adiponectin, prolactin,
and interleukin-6 (Borcherding et al., 2011). However, more
studies are needed to clarify and test the hypothesis that
dopamine is a potential modulator of insulin signaling, glucose
uptake, and activation of metabolic pathways in the periphery.
In the present study, we evaluated the role of peripheral
exogenous dopamine in regulating glucose uptake, as well as
its direct effect on glucose uptake, insulin signaling, and lipid
metabolic function of insulin-sensitive tissues. Additionally, we
characterize the dopamine receptors involved in these actions.
We found that exogenous dopamine administration promotes
glucose uptake. Moreover, dopamine directly acts on insulin-
sensitive tissues through different receptors to regulate glucose
uptake and insulin receptor phosphorylation and to modulate the
metabolic function, namely, adenosine monophosphate kinase
(AMPK) phosphorylation in the liver, adipose tissue, and the
skeletal muscle and to regulate lipid metabolism–related proteins
in the adipose tissue. Therefore, we postulated that the
modulation of peripheral dopaminergic signaling in insulin-
sensitive tissues must be further evaluated as a potential
therapeutic approach to treat metabolic disorders.
MATERIALS AND METHODS
Ethical Approval
All experimental and care procedures conducted on the animals
were approved by the Ethics Committee of Faculdade de Ciencias
Médicas|Nova Medical School and by Direccao-Geral de
Alimentacao e Veterinária (DGAV), the Portuguese National
Authority for Animal Health Animal Care. Principles of
laboratory care were followed in accordance with the
European Union Directive for Protection of Vertebrates Used
for Experimental and Other Scientific Ends (2010/63/EU).
Animals
Experiments were performed on 8- to 10-week-old male Wistar
rats (200–300 g) obtained from the vivarium of the Faculdade de
Ciências Médicas|Nova Medical School, Portugal. Animals were
kept under controlled temperature and humidity (21 ± 1°C; 55 ±
10% humidity) with a 12-h light/dark cycle and ad libitum access
to food and water.
In vivo tissue-specific glucose uptake
Animals were starved overnight and randomly divided into the
control group (0.9% NaCl) versus dopamine (Medopa,
Medinfar)-injected group (100 nmol). Dopamine or saline
were administered in the tail vein in a bolus of 0.1 ml.
Immediately after dopamine or saline administration, an oral
glucose tolerance test (OGTT) with a bolus of 2-deoxy-D-
[1,2–3H]-glucose (2-DG, 1 mCi/ ml; specific activity: 8 Ci/
mmol; PerkinElmer, Madrid, Spain) mixed with glucose
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(100 μ Ci/ kg body weight; 2 g/ kg body weight) was performed by
gavage administration, to better mimic the food ingestion and all
the molecular, anatomical, histological, and immunological
characteristics of food ingestion. Glycemia was measured at
the baseline and 1 h after glucose bolus administration with a
glucometer (Precision Xtra Meter, Abbott Diabetes Care,
Portugal) and test strips (Abbott Diabetes Care, Portugal). In
order to determine glucose-specific activity, 20 µL plasma
(collected at the baseline and 1 h after glucose administration)
was deproteinized with 200 µL ice-cold perchloric acid (0.4 N)
and centrifuged, and its radioactivity was measured in a
scintillation counter (Tri-Carb 2800TR, Perkin-Elmer, Madrid,
Spain). Animals were euthanized 1 h post glucose bolus
administration with sodium pentobarbital (60 mg/kg, i. p) and
tissues, such as the liver, soleus muscle, and white (WAT:
mesenteric, mWAT; epidydimal, eWAT) and brown adipose
tissues (BAT), were collected (50–200 mg) and homogenized
in 1 ml ice-cold perchloric acid (0.4 N). Tissue samples were
centrifuged and 2-deoxy-D-[3H]glucose incorporation was
measured in the supernatants by scintillation counting. Tissue
glucose uptake (defined as the glucose metabolic index, Rg’) was
calculated as described by Sacramento et al. (2017) (Figure 1)
(Sacramento et al., 2017).
Ex vivo tissue-specific glucose uptake
After an episode of overnight fasting, the animals were
euthanized with sodium pentobarbital (60 mg/ kg, i. p.) and
the liver, soleus, and WAT (mesenteric, mWAT, and
epididymal eWAT) (50–150 mg) samples were rapidly
collected in an ice-cold 21%O2/5%CO2-equilibrated tyrode
solution (in mM: 140 NaCl, 5 KCl, 2 CaCl2, 1.1 MgCl2, 10
HEPES, and 5.5 glucose, pH 7.40). Three to four pieces of the
tissue per Eppendorf tube (2 ml) were then incubated at 37°C for
15 min for stabilization and afterward moved to other tubes for
incubation for 15 min per piece in different experimental
conditions. Different tissues samples were incubated in the
presence and absence of insulin (10 mUml−1) together with
dopamine (10 µM); dopamine plus domperidone (50 nM);
dopamine plus haloperidol (500 nM), bromocriptine (10 μM,
kindly provided by Generis (Portugal)); bromocriptine plus
domperidone; and bromocriptine plus haloperidol. The
samples were then incubated with 2-deoxy-D-[1,2–3H]-glucose
for 30 min and homogenized. Uptake of 2-deoxy-D-[1,2–3H]-
glucose was performed as described in the previous section.
Results were expressed in cpm.mg tissue−1 (Figure 1).
Drug concentrations were chosen with an aim to achieve the
complete activation of receptors, and therefore were 10–100x
higher than the respective EC50 for agonists and IC50 as
described for antagonists. The dopamine concentration tested
was based on previous data obtained in vivo by our laboratory for
the modulation of blood pressure and ventilation Monteiro et al.
(2011) and for glucose uptake (Tavares et al., 2020).
Bromocriptine was tested in two concentrations that mainly
act on D2R (10 and 50 µM) (Beaulieu et al., 2019), but since
there were no statistical differences between the doses tested, the
dose of 50 µM promoted a less pronounced effect (data not
FIGURE 1 | A methodological overview for the in vivo and ex vivo experiments aimed to study the role of peripheral dopamine on insulin-sensitive tissues.
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shown), meaning that we have probably reached the maximal
efficacy of the drug, or that we are probably producing a
desensitization of the receptor, we used at the lowest
concentration. Haloperidol was used in a dose that blocks
both D1R and D2R (Beaulieu et al., 2019).
Western Blot for Analysis of IR, Akt, AMPK,
HSL, ACC, and ACL Phosphorylation
For Western blot analyses, tissue explants were collected and
immediately stored at−80oC after a 15-min incubation under
different experimental conditions. Tissue explants (100 mg/ ml,
n  5–9) were homogenized and processed for Western blot as
previously described by Matafome (Matafome et al., 2012). Primary
antibodies to the phosphorylated forms of insulin receptor (InsR,
Tyr972, ab5678), protein kinase B (PKB), also known as Akt (Akt,
Ser473, #4058S), adenosine monophosphate kinase (AMPK,
Thr172, #2535S), hormone sensitive lipase (HSL, Ser563, #4139S),
acetyl CoA carboxylase (ACC, Ser79, #11818P), and ATP citrate
lyase (ACL, Ser455 #4331P) were obtained from Abcam
(Cambridge, United Kingdom) or Cell Signalling Technology
(Danvers, United States). Calnexin (AB0041-200) from SICGEN
(Cantanhede, Portugal) was used as the loading control. Secondary
antibodies of anti-rabbit and anti-goat samples were obtained from
Bio-Rad (Spain) and Invitrogen or Thermo Fisher Scientific
(United States), respectively. Membranes were revealed using an
ECL substrate (Advansta, CA, United States) in a VersaDoc system
(Bio-Rad, United States) and analyzed with ImageQuant®
(Molecular Dynamics, United States).
Data Analysis and Statistical Procedures
In glucose uptake experiments, a piece of each evaluated tissue
(from a minimum of five animals per condition) was used and
incubated with dopamine or its agonists and antagonists. For
statistical analyses, all data were evaluated using GraphPad Prism
Software, version 8 (GraphPad Software Inc., United States) and
presented as scatter plots or mean values with standard deviation
(SD). Significance between the mean values was calculated by the
one-way ANOVA with Dunnets’s and Bonferroni multiple
comparison tests. Differences were considered significant at
p < 0.05.
RESULTS
Peripheral dopamine mediates in vivo tissue glucose uptake.
Dopamine (100 nmol) was administered intravenously
immediately before oral glucose administration. Figure 2
presents the effect of dopamine on glucose uptake in insulin-
sensitive tissues. The soleus muscle and BAT exhibited a higher
glucose uptake in relation to the rest of the tissues, showing that
these are tissues with a high rate of glucose uptake (baseline liver
2.03; mWAT  2.18; eWAT  1.30; Soleus  3.73; and BAT 
4.73 mmol/ mg tissue). Dopamine significantly increases glucose
uptake in all the tissues tested, except mWAT, producing an
increase of 49% in the liver, 88% in eWAT, 70% in the soleus
muscle, and 88% in BAT.
Dopamine Directly Acts in Insulin-Sensitive
Tissues Through Different Receptors to
Regulate Glucose Uptake
Aiming to clarify the contribution of the specific dopamine
receptors role in each insulin-sensitive tissue, ex vivo tissue
uptake of glucose studies was performed; thus, insulin-
sensitive tissues were incubated with selective dopamine
receptor’s agonists and antagonists.
Dopamine effect on glucose uptake in the liver: Insulin
significantly increased glucose uptake by 37% in the liver
(control  31 cpmmin−1) (Figure 3A). Dopamine alone or in
the presence of domperidone did not change glucose uptake in
the liver (Figure 3A). However, dopamine + insulin-induced
increase of glucose uptake was abolished by domperidone (26%
decrease, Figure 3A), suggesting that dopamine D2R has a role in
the insulin effect on glucose uptake in the liver. This was further
suggested by the significant increase in glucose uptake by 48% in
response to bromocriptine, an effect that was independent and
additive to insulin-induced glucose uptake (Figure 3A).
Domperidone inhibited this effect of bromocriptine,
confirming the dopamine D2R-mediated effect.
Dopamine induces glucose uptake in the skeletal muscle
via dopamine D1R: The skeletal muscle is a major organ
involved in glucose homeostasis and therefore herein we
FIGURE 2 | Effects of in vivo dopamine administration on glucose uptake in insulin-sensitive tissues. Exogenous dopamine administration at 100 nmol enhances
glucose uptake significantly in all tissues except for mWAT. Values and bars represent mean ± SD. One-way ANOVA with Dunnet’s post hoc comparisons test was
performed, where * indicates different from the control group. Levels of significance: *p < 0.05; **p < 0.01; ***p < 0.001. mWAT, mesenteric white adipose tissue; eWAT,
epididymal white adipose tissue; and BAT, brown adipose tissue.
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evaluated the role of dopamine signaling in skeletal muscle
glucose uptake. Similar to insulin, dopamine applied alone
significantly increased glucose uptake by 47%, an effect not
mimicked by bromocriptine stimulation, suggesting a
dopamine D1R-mediated mechanism (Figure 3B). This was
confirmed using haloperidol, in a dose that blocks both
dopamine D1 and D2 receptors, as it inhibits the effect of
dopamine on glucose uptake.
Dopamine potentiated insulin-induced glucose uptake in
mWAT via dopamine D2R: Finally, to understand the role of
dopaminergic signaling in WAT depots with different metabolic
functions, mWAT and eWAT were also studied ex vivo.
Dopamine or bromocriptine did not alter glucose uptake in
both tissues (Figures 3C,D). Nevertheless, in mWAT but not
in eWAT, both dopamine and bromocriptine potentiated insulin-
mediated glucose uptake (38 and 72% vs. 162 and 185%,
respectively) in comparison with the control group (35 cpm/
mg tissue, Figure 3C). This last effect was blocked by the presence
of domperidone, confirming a dopamine D2R-dependent
mechanism. Interestingly dopamine and bromocriptine did not
change the ex vivo glucose uptake or potentiate the effect of
insulin (Supplemental figure 1A).
Dopamine Differently Regulates Insulin
Signaling in Insulin-Sensitive Tissues
Bromocriptine-induced glucose uptake in the liver is independent
of the InsR. To disclose the role of dopamine in insulin signaling,
the levels of InsR phosphorylated at Tyr972 (InsR-Tyr972) were
determined byWestern blot. As depicted in Figure 4A, incubation
with dopamine and bromocriptine did not change liver InsR-Tyr972
levels. However, since domperidone in the presence of bromocriptine
and insulin increased the phosphorylation of InsR by 58% in
comparison with the control group and 51% in comparison with
bromocriptine (Figure 4A), we can speculate that dopamine D2R is
involved in other InsR-induced mechanisms different from glucose
uptake regulation.
Dopamine induces InsR phosphorylation in the skeletal muscle:
In the skeletal muscle, insulin and dopamine applied separately were
able to induce InsR phosphorylation, by 8 and 18%, but when
applied together the effect was not modified, suggesting that they act
on the same signaling pathway (Figure 4B). Haloperidol decreased
dopamine and dopamine plus insulin effects on InsR-Tyr972 levels
by 22 and 38%, respectively (Figure 4B), an effect mimicked by
domperidone, a selective dopamine D2R agonist (Figure 4B).
FIGURE 3 | Role of dopamine and bromocriptine on ex vivo glucose uptake in the liver (A), soleus muscle (B), mWAT (C), and eWAT (D). The effect of dopamine
(10 μM, blue bars) and bromocriptine, a D2R agonist (10 μM, orange bars), on 2-deoxy-D-[1,2–3H]-glucose uptake in the presence and absence of insulin (10m U ml-1)
and its blockade by domperidone, a D2R antagonist (50 nM) and/or haloperidol (500 nM) a D1R and D2R antagonist in the liver, the soleus muscle, mWAT, and eWAT.
Bars represent means ± SD. One-way ANOVA with Dunnet’s post hoc comparison test * vs. control; # vs. insulin; $ vs. dopamine, & vs. bromocriptine. Levels of
significance: * p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001. mWAT, mesenteric white adipose tissue; eWAT, epididymal white adipose tissue; D1R, dopamine
receptor 1; and D2R, dopamine receptor type 2.
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Dopamine-induced potentiation of insulin action in WAT is
independent of the InsR: Insulin significantly increased InsR
phosphorylation by 24% in the mWAT and by 46% in eWAT,
respectively (Figures 4C,D), but not in BAT (Supplemental figure
1B). Dopamine or bromocriptine alone or in the presence of insulin
did not alter InsR-Tyr972 phosphorylation in both tissues (Figures
4C,D). Nevertheless, an increase in the InsR-Tyr972 levels in
mWAT and eWAT was observed when domperidone was added
to the condition dopamine + insulin (82 and 274%) and
bromocriptine + insulin (49 and 81%) (Figures 4C,D), suggesting
that, as observed in the liver, dopamine D2R plays a role in other
InsR-induced mechanisms than glucose uptake.
Dopamine Regulates AMPK Activation in
Insulin-Sensitive Tissues
Dopamine D2R is involved in the AMPK function in the liver: We
also evaluated the impact of dopaminergic signaling on AMPK
activation, an energy sensor that has a key role in the control
of energy metabolism, by regulating hepatic glucose and lipid
metabolism, through Thr172 phosphorylation. In the liver, a
significant reduction of 26 and 21% was observed when
domperidone was added to bromocriptine and to bromocriptine
+ insulin, respectively, in comparison with the control group. This
suggests that dopamine D2R activation is necessary for AMPK
function in the liver (Figure 5A).
FIGURE 4 | Effect of dopamine and bromocriptine on insulin receptor phosphorylation in the liver (A), soleus muscle (B), mWAT (C), and eWAT (D). Effect of
dopamine (10 μM, blue bars) and bromocriptine, a D2R agonist (10 μM, orange bars), on insulin receptor phosphorylation (InsR) in the presence and absence of insulin
(10m U ml−1) and its blockade by domperidone, a D2R antagonist (50 nM) and/or haloperidol (500 nM), a D1R and D2R antagonist in the liver, the soleus muscle,
mWAT, and eWAT. The top of the figures show representative Western blots for the effect of dopamine and bromocriptine on InsR-Tyr972 (97 kDa band)
phosphorylation, in the presence and absence of insulin and its blockade by domperidone and/or haloperidol. Calnexin was used as the loading control (83 kDa band).
Bars represent mean ± SD of the expression of InsR-Tyr972. On the bottom of the bars are shown the different conditions used for each group tested with + meaning
presence of that stimuli and – absence of it. One-way ANOVA with Dunnet’s post hoc comparison test * vs control; # vs. insulin; $ vs. dopamine; & vs. bromocriptine.
Levels of significance: * p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001. mWAT, mesenteric white adipose tissue; eWAT, epididymal white adipose tissue; D1R,
dopamine receptor type 1; and D2R, dopamine receptor type 2.
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Dopamine activates AMPK in the skeletal muscle: Insulin
significantly increased AMPK phosphorylation by 29% in the
soleus muscle (Figure 5B). Dopamine and bromocriptine alone
increased by 47 and 73% AMPK phosphorylation levels, effects
that were not modified in the presence of insulin (Figure 5B).
These effects were blocked by haloperidol and
domperidone–dopamine D1R + D2R and selective dopamine
D2R antagonists, respectively, suggesting that the effects of
dopamine and bromocriptine on AMPK phosphorylation are
mediated by dopamine D2 receptors.
Dopamine D2R inhibits AMPK activation in the adipose
tissue: In mWAT, dopamine and bromocriptine did not alter
AMPK-Thr172 levels compared to the control group
(Figure 5C). On the other hand, in eWAT, while dopamine
did not affect AMPK-Thr172 phosphorylation, bromocriptine
decreased AMPK-Thr172 phosphorylation by 44% when
compared to the control group (Figure 5D). Incubation with
dopamine or bromocriptine in the presence of domperidone +
insulin significantly increased the levels of AMPK-Thr172 in
eWAT by 48 and 90%, respectively (Figure 5D), and a similar
trend was observed in mWAT (Figure 5C). Such results suggest
an inhibitory effect of dopamine D2R on AMPK phosphorylation
on the white adipose tissue. No significant changes were observed
for the effects of dopamine and/or bromocriptine on AMPK
phosphorylation in BAT (Supplemental figure 1C).
Inhibition of dopamine D2 receptor increases dopamine-
mediated stimulation of adipose tissue lipid catabolic
pathways. As expected, Akt-Ser473 phosphorylation increased
with insulin incubation in bothmWAT and eWAT (73 and 152%,
respectively) compared to control conditions (Figures 6A,B,
respectively). Dopamine or the dopamine D2R agonist,
bromocriptine when applied alone did not increase Akt-Ser473
phosphorylation levels in both WAT depots or changed insulin-
mediated increase in Akt-Ser473 levels (Figures 6A,B). These
FIGURE 5 | Involvement of dopamine and bromocriptine on AMPK phosphorylation in the liver (A), soleusmuscle (B)mWAT (C), and eWAT (D). Effect of dopamine
(10 μM, blue bars) and bromocriptine (10 μM, orange bars) on AMPK phosphorylation in the presence and absence of insulin (10m U ml−1) and its blockade by
domperidone, a D2R antagonist (50 nM) and/or haloperidol (500 nM), a D1R and D2R antagonist in the liver, soleus muscle, and mesenteric and epididymal adipose
tissue. The top of figures shows representativeWestern blots for the effect of dopamine and bromocriptine on AMPK-Thr172 (62 kDa band) phosphorylation, in the
presence and absence of insulin, and its blockade by domperidone and/or haloperidol. Calnexin was used as the loading control (83 kDa band). Bars represent mean ±
SD. On the bottom of the bars are shown the different conditions used for each group tested with + meaning presence of that stimuli and – absence of it. One-way
ANOVAwith Dunnet’s post hoc comparison test * vs. control; # vs. insulin; $ vs. dopamine; & vs. bromocriptine. Levels of significance: * p < 0.05; **p < 0.01; ***p < 0.001;
**** p < 0.0001. mWAT, mesenteric white adipose tissue; eWAT, epididymal white adipose tissue; D1R, dopamine receptor type 1; and D2R, dopamine receptor type 2.
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results suggest that both dopamine and bromocriptine exert their
actions independent of insulin receptor pathway activation, since
Akt-Ser473 is a downstream modulator of InsR signaling
(Figures 6A,B).
To understand the implications of dopaminergic signaling on
lipid metabolism pathways, we evaluated HSL, ACC, and ACL
activation through the measurement of their phosphorylated
forms: HSL-Ser563, ACC-Ser79 (inhibitory), and ACL-Ser455.
FIGURE 6 | Involvement of dopamine and bromocriptine on Akt (A,B), HSL (C,D), ACC (E,F), and ACL (G,H) phosphorylation in mWAT and eWAT, respectively.
Figures show the effect of dopamine (10 μM, blue bars) and the effect of bromocriptine (10 μM, orange bars) onmWAT and eWAT. Akt (A,B), HSL (C,D), ACC (E,F), and
ACL (G,H) phosphorylation, and its blockade by domperidone (50 nM). The insulin dose used was 10m U ml−1. The top of figures show representative Western blots
for the effect of insulin, dopamine, and bromocriptine in the presence or absence of domperidone, a D2R antagonist, on Akt-Ser743 (A,B), HSL-Ser563 (C,D),
ACC-Ser79 (E,F), and ACL-Ser455 (G,H) phosphorylation, where the bands on the top represent calnexin (83 kDa band), the loading control, and the bands below
show the proteins of interest–Akt-Ser743, HSL-Ser563, ACC-Ser79, and ACL-Ser455. Bars represent means ± SD. On the bottom of the bars are shown the different
conditions used for each group tested with + meaning presence of that stimuli and – absence of it. One-way ANOVA with Dunnet’s post hoc comparison test * vs.
control; # vs. insulin; $ vs. dopamine; & vs. bromocriptine. Levels of significance: * p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001. mWAT, mesenteric white adipose
tissue; eWAT, epididymal white adipose tissue; and D2R, dopamine receptor type 2.
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Insulin increased by 35% and HSL-Ser563 levels by 73% in
mWAT and eWAT depots, respectively (Figures 6C,D).
Interestingly, in both fat depots, dopamine or bromocriptine
alone did not change HSL-Ser563 levels Figures 6C,D), but in
the presence of domperidone + insulin, HSL-Ser563 levels
significantly increased in mWAT and eWAT compared to
dopamine (114 and 148%) or to bromocriptine (73%, and
217%), respectively (Figures 6C,D).
Interestingly, both dopamine and bromocriptine directly
decreased by 50 and 66%, respectively, ACC-Ser79
phosphorylation levels in eWAT, meaning that these substances
decreased ACC activity (Figures 6E,F). This effect was not
observed in mWAT (Figures 6E,F). ACC-Ser79 levels were
significantly increased in mWAT and eWAT in the presence of
domperidone in combination with all the other tested conditions
(Figures 6E,F), which is consistentwith increasedAMPKactivation in
the same condition, a known inhibitor of ACC. Dopamine and
bromocriptine did not present a direct effect on ACL
phosphorylation, but domperidone in the presence of insulin
significantly increased ACL-Ser455 levels in mWAT and eWAT by
298 and 156%, respectively, when compared to dopamine, and by 304
and 390%, respectively, when compared to bromocriptine
(Figures 6G,H).
Altogether, our data suggest that dopamine D2R is involved in
glucose uptake–independent activation of InsR and in the
regulation of pathways associated with lipid metabolism in
WAT, by impacting on the expression of phosphorylated
forms of AMPK, HSL, ACC, and ACL in both WAT depots.
DISCUSSION
Herein, we described for the first time the direct effects of dopamine
(mediated by different dopamine receptor activation) in glucose
uptake andmetabolism in insulin sensitivity tissues.We showed that
peripheral dopamine stimulates glucose uptake in several tissues, in
part through direct actions in the liver, the skeletal muscle, and
WAT. Moreover, dopamine receptors, especially dopamine D2R,
play a role in these tissues in the regulation of InsR, Akt, and AMPK
phosphorylation. Also, dopamine D2R is involved in the regulation
of lipid metabolism pathways in WAT, which could be relevant for
unraveling new therapeutic approaches for obesity-related diseases.
Herein, we also show that dopamine effects on glucose uptake occur
preferentially through dopamine D1R in the skeletal muscle and
through dopamine D2R in the liver and WAT (Table 1).
Dopamine effects on glucose metabolism were attributed for
many years to the regulation of the central nervous system
(DeFronzo, 2011; Lopez Vicchi et al., 2016), supported by the
alterations in peripheral metabolism produced by antipsychotics
(Lopez Vicchi et al., 2016; Freyberg and McCarthy, 2017). In
agreement, the effects of bromocriptine, a dopamine D2 receptor
agonist, on glucose metabolism have been attributed to the central
regulation of sympathetic nervous system activity (DeFronzo, 2011).
However, with the identification of dopamine receptors in the
pancreas and in the adipose tissue, and the description of its
involvement in the regulation of insulin and adipokines secretion
(Borcherding et al., 2011; Chaudhry et al., 2016; Farino et al., 2019),
the peripheral role of dopamine needs to be considered. The results
obtained in the present study agree with the role of peripheral
dopamine on glucose metabolism, as we show a direct effect of
dopamine on tissues outside the central nervous system in the
regulation of glucose and lipid metabolic pathways. Moreover,
both dopamine receptors participate in this modulation playing
distinct roles in the different insulin-sensitive tissues.
We showed in vivo that peripheral dopamine administration
during an OGTT produces an overall enhancement of tissue glucose
uptake by the insulin-sensitive tissues in the liver, WAT (mesenteric
and epididymal), the soleus muscle, and BAT suggesting that
dopamine is involved in the peripheral glucose homeostasis. We
also found that dopamine directly promotes peripheral glucose
uptake in insulin sensitive tissues ex vivo, via its action on
different dopamine receptor subtypes. Interestingly, increased in
vivo glucose uptake in each tissue after dopamine administration
does not resemble the ex vivo glucose uptake in the same tissues
TABLE 1 | Summary of the findings supporting the involvement of peripheral dopamine and its receptors on glucose uptake, insulin action, AMPK signaling, and lipid storage.
Peripheral dopamine stimulates glucose uptake in the liver, the skeletal muscle, and white adipose tissue (WAT). Dopamine directly acts in the same tissues to regulate
InsR, Akt, and AMPK phosphorylation, being also involved in the regulation of metabolic functions in WAT, which can be an important factor for obesity-related diseases.
Dopamine-directed effects in insulin-sensitive tissues are differentially modulated by D1 and D2 dopamine receptors.
Tissue Parameter Dopamine direct effect D1 effect D2 effect








Liver Glucose uptake = = ↑↑
Insulin signaling = =
AMPK signaling ↑ ↑
Skeletal muscle Glucose uptake ↑ ↑↑ =
Insulin signaling ↑ = ↑
AMPK signaling ↑ = ↑
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upon direct dopamine or bromocriptine stimulation, showing that
dopamine may have direct and indirect effects on each of these
tissues. For example, we can postulate that when administered
systemically in vivo, dopamine may act to decrease sympathetic
activation to efferent organs changing the metabolic turnover and
the release of signaling molecules that will act distant from the
releasing cells, as seen previously with other mediators (Guilherme
et al., 2019). An example of this kind of mechanism is the regulation
of adipokines secreted by WAT that will act on BAT to change its
metabolic status (Guilherme et al., 2019). Another counter-
regulatory mechanism that we can postulate to be involved in the
regulation of peripheral dopamine effects could be themodulation of
parasympathetic activity through the vagus nerve. It is known that
the parasympathetic vagus nerve mediates changes in BAT
sympathetic activity and energy expenditure in response to
altered efferent signaling coming from tissues such as the liver
and WAT (Madden and Morrison, 2016). Finally, we can
speculate that the use of alternative fuels by the other tissues in
in vivo experiments can be responsible for the forwarding of glucose
to BAT and consequent increase in glucose uptake (Stanley et al.,
2019).
Herein, we also found for thefirst time differences on the dopamine
receptors involved in the regulation of glucose uptake measured ex
vivo. The dopamine D2R agonist directly stimulated glucose uptake in
the liver, while in the soleus, even though dopamine stimulates glucose
uptake, we cannot find any alterations with bromocriptine incubation,
pointing out an involvement of dopamine D1 receptors in glucose
uptake in the skeletal muscle. In the adipose tissue, dopamine D2R
stimulation only potentiated the effect of insulin on glucose uptake,
independently of InsR activation.Our results suggest an important and
tissue-specific role of dopamine in the regulation of glucose uptake.
Moreover, our results raised some questions or hypotheses regarding
the involvement of dopamine receptors in the regulation of glucose
uptake and glucose transporters, GLUTs. Given the difference between
glucose transporters in the liver (insulin-independent GLUT2) and the
muscle and adipose tissue (insulin-dependent GLUT4) (Navale and
Paranjape, 2016), it seems expectable that dopamine-mediated glucose
uptake may be dependent on the type of GLUT translocated to the
plasma membrane.
Interestingly, domperidone induced InsR-Tyr972
phosphorylation in the liver and InsR-Tyr972 and Akt-Ser473
phosphorylation in WAT without any evident increase in glucose
uptake, suggesting that the dopamine D2R impact on insulin
signaling on these tissues exerts other metabolic effects in cells
apart from glucose uptake. Altogether, the results of dopamine
receptors modulation herein described point toward a major role
of dopamine D2R in the peripheral control of glucose metabolism in
the insulin-sensitive tissues with the exception of the soleus muscle
where dopamine D1R appears to be a modulator of glucose uptake.
Additionally, from our results, it is clear that dopamine D2R
potentiated insulin–glucose uptake at mWAT, suggesting an
interaction between insulin and dopamine signaling pathways
to control glucose uptake in this tissue, while in the soleus muscle
and the liver the effect seems to be additive. This is corroborated
by the fact that dopamine- and bromocriptine-mediated glucose
uptake in WAT is independent of InsR and Akt activation
(downstream regulator of InsR pathway signaling) since
phosphorylation of both proteins is only stimulated by insulin.
Dopamine is known to act on dopamine D1R andD2R to regulate
cAMP levels inside the cell, regulating neuronal excitability
through membrane availability of ion channels (Savica and
Benarroch, 2014). Apart from the classical activation of the
Gαi/o protein coupled to dopamine D2R and thereby the
inhibition of adenylate cyclase, it is known that dopamine
D2R has several effectors (Thummel, 2005) that can account
for the effects herein observed for dopamine in WAT.
In the present study, we also describe for the first time that
dopamine receptors regulate AMPK phosphorylation in eWAT and
in the skeletal muscle. Interestingly, these effects were opposite since
dopamine decreased AMPK phosphorylation in eWAT via
dopamine D2R, while enhanced AMPK phosphorylation in the
soleus muscle upon stimulation with dopamine and bromocriptine.
Confirming the dopamine D2Rmodulation, the effects of dopamine
D2R agonism on the soleus muscle AMPK phosphorylation were
reversed by D2R antagonism.
We also show that dopamine D1 receptors modulate glucose
uptake in the skeletal muscle, suggesting different pathways
mediating metabolism in the soleus muscle. Nevertheless, we
cannot forget that AMPK also facilitates GLUT4 translocation to
the plasma membrane (Wolfe, 1998; Mihaylova and Shaw, 2011) and
therefore we can speculate that D2R modulation might contribute
indirectly to glucose uptake as well. The exact mechanism by which
dopamine D2R increases AMPK-Thr172 levels in the skeletal muscle
is not clearly understood and therefore more experiments will be
needed in the future to clarify this.
On the other hand, dopamineD2R inhibition by domperidone in
the presence of dopamine increased HSL, ACC, and ACL
phosphorylation, and therefore activates HSL and ACL pathways
and inactivates the ACC pathway, in both mWAT and eWAT
showing dopamine involvement in lipid metabolism pathway
modulation in the adipose tissue. HSL and ACL are involved in
lipid catabolism pathways, so we can speculate that dopamine D2R
inhibition promotes lipid oxidation in the adipose tissue. Regarding
ACC, its main function is to catalyze lipogenesis, and therefore
domperidone, by inactivating this enzyme, will promote a decrease
in fatty acid synthesis and a shift of lipid metabolism in lipolytic
pathways. This, together with HSL and ACL activation, will improve
lipid metabolism in the adipose tissue and therefore will benefit
metabolic disease treatment. Moreover, we recently described that
bromocriptine treatment in GK rats, a type 2 diabetes rat model,
upregulates catabolic pathways, improving the metabolic profile
(Tavares et al., 2021). Altogether, we can clearly say that
dopamine receptors modulate lipid metabolism in the adipose
tissue, although one might find these results contradictory.
However, we must take into account that in the present study,
we are evaluating the acute effects of dopamine and the modulation
of its receptors; moreover, we are in the absence of metabolic disease,
which is described to alter dopamine receptors expression in the
adipose tissue (Tavares et al., 2021).
Of note, we cannot forget the possibility of dopamine receptor
heterodimerization on the interpretation of the results obtained in
the present study, particularly between D1R and D2R. The
formation of heterodimers between D2R and D1R are well
established in the brain as described, for instance, by Abraham
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et al. (2014); however, there are no studies regarding this type of
heterodimerization in the peripheral organs. Yet, an interaction
between those on the activation of adenylyl cyclase and on the
production of cAMP has been postulated to regulate insulin
secretion from beta cells Bucolo et al. (2019) and to be on the
basis of some of the bromocriptine effects in the periphery (Bucolo
et al., 2019). Also, interestingly, heterodimerization between D2–D3
receptors has been found in the pancreas. These receptors belong to
the same subtype family—the D2-like family—enabling the
intensification/enhancement of the intracellular pathway response,
in contrast to what happens with a D2R–D1R heterodimerization
(Abraham et al., 2014; Maffei et al., 2015; Farino et al., 2019).
Moreover, we cannot also forget that dopamine D2R receptors are
known to heterodimerize with adenosine and serotonin receptors
(Conde et al., 2008; Łukasiewicz et al., 2010; Feltmann et al., 2018;
Bucolo et al., 2019) and that adenosine is known to play a major role
in glucose homeostasis (Sacramento et al., 2020).
Overall, we found that peripheral dopamine modulates glucose
uptake through direct and indirect actions in insulin-sensitive
tissues. Dopamine D1R and D2R are differentially involved in
glucose uptake and regulation of the insulin signaling pathway and
AMPK phosphorylation in insulin-sensitive tissues. Particularly,
dopamine via D1R regulates glucose uptake in the soleus muscle,
while via D2R regulates glucose uptake in the liver and WAT.
Importantly, we found that dopamine also impacts lipid
metabolism pathways in WAT, showing its importance for
obesity. Nevertheless, the direct effects of dopamine only
partially explain the tissue glucose uptake observed after its in
vivo peripheral administration. Given that dopamine is not able to
cross the blood–brain barrier, other peripheral indirect mechanisms
of glucose homeostasis regulation by dopaminemay be involved and
should be addressed in the future. The present study adds knowledge
about the peripheral dopaminergic signaling role over glucose
uptake to the already described mechanisms. These results can
support the effects of bromocriptine treatment in type 2 diabetes and
contribute to the identification of new therapeutic strategies, based
on the modulation of dopaminergic signaling, for the treatment of
metabolic disorders such as type 2 diabetes, obesity, and metabolic
syndrome.
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